Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia: Results of a phase 3 randomized double-blind placebo-controlled study

被引：0
|
作者：
Zelenetz, A. [1 ]
Robak, T. [2 ,3 ]
Coiffier, B. [4 ]
Delgado, J. [5 ]
Marlton, P. [6 ]
Adewoye, A. [7 ]
Kim, Y. [7 ]
Dreiling, L. [7 ]
Hillmen, P. [8 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA
[2] Med Univ Lodz, Lodz, Poland
[3] Copernicus Mem Hosp, Lodz, Poland
[4] Hosp Civils Lyon, Pierre Benite, France
[5] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain
[6] Princess Alexandra Hosp, Dept Clin Haematol, Brisbane, Qld 4102, Australia
[7] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[8] St James Univ Hosp, Dept Haematol Oncol, Leeds LS9 7TF, W Yorkshire, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2016年 / 173卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
10
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [41] Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the Phase 3 Double-Blind HELIOS Trial
    Chanan-Khan, Asher
    Cramer, Paula
    Fraser, Graeme
    Silva, Rodrigo Santucci
    Grosicki, Sebastian
    Pristupa, Aleksander
    Dilhuydy, Marie Sarah
    Goy, Andre
    Mato, Anthony R.
    Damle, Rajendra
    Phelps, Charles
    Mahler, Michelle
    Salman, Mariya
    Schaffer, Michael
    Howes, Angela
    Balasubramanian, Sriram
    BLOOD, 2015, 126 (23)
  • [42] Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
    Sharman, Jeff P.
    Coutre, Steven E.
    Furman, Richard R.
    Cheson, Bruce D.
    Pagel, John M.
    Hillmen, Peter
    Barrientos, Jacqueline C.
    Zelenetz, Andrew D.
    Kipps, Thomas J.
    Flinn, Ian W.
    Ghia, Paolo
    Eradat, Herbert
    Ervin, Thomas
    Lamanna, Nicole
    Coiffier, Bertrand
    Pettitt, Andrew R.
    Ma, Shuo
    Tausch, Eugen
    Cramer, Paula
    Huang, Julie
    Mitra, Siddhartha
    Hallek, Michael
    O'Brien, Susan M.
    Stilgenbauer, Stephan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (16) : 1391 - +
  • [43] Sequoia: Results of a randomized phase iii trial of zanubrutinib versus bendamustine plus rituximab (br) in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Greil, R.
    Robak, T.
    Giannopoulos, K.
    Jurczak, W.
    Simkovic, M.
    Shadman, M.
    Oesterborg, A.
    Laurenti, L.
    Walker, P.
    Opat, S.
    Chan, H.
    Ciepluch, H.
    Tani, M.
    Trneny, M.
    Brander, D. M.
    Flinn, I. W.
    Grosicki, S.
    Verner, E.
    Brown, J. R.
    Kahl, B. S.
    Ghia, P.
    Li, J.
    Tian, T.
    Zhou, L.
    Marimpietri, C.
    Paik, J. C.
    Cohen, A.
    Hillmen, P.
    Tam, C. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 117 - 118
  • [44] GLANCE Results of a phase 2, randomized, double-blind, placebo-controlled study
    Goodman, A. D.
    Rossman, H.
    Bar-Or, A.
    Miller, A.
    Miller, D. H.
    Schmierer, K.
    Lublin, F.
    Khan, O.
    Bormann, N. M.
    Yang, M.
    Panzara, M. A.
    Sandrock, A. W.
    NEUROLOGY, 2009, 72 (09) : 806 - 812
  • [45] Randomized, double-blind, placebo-controlled phase 3 study of ibrutinib plus rituximab in patients with previously untreated marginal zone lymphoma (MZL).
    Noy, Ariela
    Hughes, Stephanie
    Biggar, Erin
    Bogdan, Matthew
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
    Fischer, Kirsten
    Cramer, Paula
    Busch, Raymonde
    Stilgenbauer, Stephan
    Bahlo, Jasmin
    Schweighofer, Carmen D.
    Boettcher, Sebastian
    Staib, Peter
    Kiehl, Michael
    Eckart, Michael J.
    Kranz, Gabriele
    Goede, Valentin
    Elter, Thomas
    Buehler, Andreas
    Winkler, Dirk
    Kneba, Michael
    Doehner, Hartmut
    Eichhorst, Barbara F.
    Hallek, Michael
    Wendtner, Clemens-Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (26) : 3559 - 3566
  • [47] Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
    Chanan-Khan, Asher
    Cramer, Paula
    Demirkan, Fatih
    Fraser, Graeme
    Silva, Rodrigo Santucci
    Grosicki, Sebastian
    Pristupa, Aleksander
    Janssens, Ann
    Mayer, Jiri
    Bartlett, Nancy L.
    Dilhuydy, Marie-Sarah
    Pylypenko, Halyna
    Loscertales, Javier
    Avigdor, Abraham
    Rule, Simon
    Villa, Diego
    Samoilova, Olga
    Panagiotidis, Panagiots
    Goy, Andre
    Mato, Anthony
    Pavlovsky, Miguel A.
    Karlsson, Claes
    Mahler, Michelle
    Salman, Mariya
    Sun, Steven
    Phelps, Charles
    Balasubramanian, Sriram
    Howes, Angela
    Hallek, Michael
    Assouline, S.
    Bence-Bruckler, I.
    Buckstein, R.
    Fraser, G.
    Larratt, L.
    Minuk, L.
    Villa, D.
    Angevine, A.
    Bartlett, N.
    Bixby, D.
    Caimi, P.
    Chanan-Khan, A.
    Craig, M.
    Forero-Torres, A.
    Ganguly, S.
    Goy, A.
    Heffner, L.
    Hermann, R.
    Lansigan, F.
    Leis, J.
    Letzer, J.
    LANCET ONCOLOGY, 2016, 17 (02): : 200 - 211
  • [48] IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY
    Cramer, P.
    Chanan-Khan, A.
    Demirkan, F.
    Fraser, G.
    Santucci Silva, R.
    Pylypenko, H.
    Grosicki, S.
    Janssens, A.
    Pristupa, A.
    Mayer, J.
    Dilhuydy, M. S.
    Loscertales, J.
    Bartlett, N. L.
    Avigdor, A.
    Rule, S.
    Sun, S.
    Mahler, M.
    Salman, M.
    Howes, A.
    Hallek, M.
    HAEMATOLOGICA, 2015, 100 : 55 - 56
  • [49] Long-Term Follow-up of a Phase 1 Trial of Idelalisib (ZYDELIG®) in Combination with Bendamustine (B), Bendamustine/Rituximab (BR), Fludarabine (F), Chlorambucil (Chl), or Chlorambucil/Rituximab (ChlR) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Barrientos, Jacqueline C.
    Coutre, Steven E.
    de Vos, Sven
    Wagner-Johnston, Nina D.
    Flinn, Ian W.
    Sharman, Jeff P.
    Schreeder, Marshall T.
    Boyd, Thomas E.
    Rai, Kanti R.
    Leonard, John P.
    Kim, Yeonhee
    Viggiano, Anthony
    Jahn, Thomas M.
    Furman, Richard R.
    BLOOD, 2014, 124 (21)
  • [50] Final 5-Year Updated Results From a Phase 3 Study (HELIOS) of Ibrutinib Plus Bendamustine and Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 17 - 19
12345